tldrdailynews.com logo
Tag

Asco

All articles tagged with #asco

Cancer progress turns the page as survival hits 70%
future-perfect1 month ago

Cancer progress turns the page as survival hits 70%

At the 2026 ASCO meeting, a line graph showing daraxonrasib nearly doubling median survival for a form of advanced pancreatic cancer sparked a standing ovation, illustrating a broader cancer turn: US cancer deaths have fallen 34% since 1991 and the five-year survival for all cancers reached about 70% for those diagnosed 2015–2021, driven by immunotherapy, vaccines, and CAR‑T therapy; yet high drug costs and, more worryingly, funding cuts to NIH/NSF risk slowing the scientific engine behind these gains.

via vox.com|
#asco#cancer-progress#future-perfect
Smart drugs and precision medicine reshape cancer care at ASCO 2026
health1 month ago

Smart drugs and precision medicine reshape cancer care at ASCO 2026

At ASCO 2026, researchers showcased ‘smart’ drugs that lift cancer cells’ invisibility cloaks to boost immunotherapy, with GRWD5769 plus cemiplimab shrinking tumors across several cancer types; other agents like ivonescimab and ozekibart show promise. A daily pill, daraxonrasib, doubled survival in metastatic pancreatic cancer, and mezigdomide added to therapy extended progression-free survival in multiple myeloma. A genomic test could allow many breast cancer patients to skip chemotherapy, while durvalumab added to chemoradiation may spare bladder-sparing surgery. Yet the Galleri multi-cancer test failed to reduce late-stage diagnoses, and rising incidence plus a looming cancer-care workforce gap stress health systems. Lifestyle changes such as better sleep and yoga may also improve outcomes for patients and survivors.

via The Guardian|
#asco#cancer#health
GLP-1 Weight-Loss Drugs Linked to Lower Breast Cancer Risk, Prompting New Trials
health1 month ago

GLP-1 Weight-Loss Drugs Linked to Lower Breast Cancer Risk, Prompting New Trials

New observational studies presented at ASCO suggest GLP-1 medications used for diabetes and weight loss (e.g., semaglutide, liraglutide) are associated with a lower incidence of breast cancer and, among those diagnosed, reduced progression and mortality. While promising, the studies cannot prove causation, and researchers are planning randomized trials to test whether GLP-1 drugs can help prevent breast cancer or improve outcomes in high-risk individuals.

via ScienceAlert|
#asco#breast-cancer#cancer-prevention
Pancreatic cancer pill daraxonrasib shows survival boost in ASCO data
world1 month ago

Pancreatic cancer pill daraxonrasib shows survival boost in ASCO data

ASCO data show Revolution Medicines’ oral daraxonrasib, a molecular glue that blocks RAS, delaying cancer symptoms by more than nine months and extending median survival to 13.2 months in advanced pancreatic cancer; while not curative, it improves length and quality of life versus chemotherapy, with side effects like rash and mouth sores that are usually manageable.

via Hindustan Times|
#asco#daraxonrasib#molecular-glue
Lilly China deals, Akeso bispecific advance, ASCO updates reshape biotech
biotech1 month ago

Lilly China deals, Akeso bispecific advance, ASCO updates reshape biotech

The Readout highlights Eli Lilly’s two China deals, Akeso’s promising lung cancer bispecific, and ASCO-driven updates on pancreatic cancer therapies (including daraxonrasib results), alongside chatter about a high-profile Chinese lung cancer therapy and a broader regulatory debate over an old peptide, illustrating how deals, trials, and policy are shaping biotech today.

via statnews.com|
#akeso#asco#biotech
SMMT Climbs on Ivonescimab Survival Edge as Keytruda Rivalry Intensifies
business1 month ago

SMMT Climbs on Ivonescimab Survival Edge as Keytruda Rivalry Intensifies

Summit Therapeutics (SMMT) surged after ASCO data showed Ivonescimab plus chemotherapy extended overall survival in advanced squamous NSCLC to 27.9 months vs 23.7 with a PD-1 inhibitor, with about 65% alive at two years versus 49% in the control. The results, independent of PD-L1 status, fuel investor optimism about Ivonescimab as a potential successor to Keytruda and have Pfizer, Bristol Myers Squibb, and Merck pursuing rival PD-(L)1xVEGF therapies. SMMT also has an FDA review for Ivonescimab in EGFR-mutated lung cancer, while retail sentiment on Stocktwits turned extremely bullish despite some regulatory questions about China-sourced data. Big Pharma stocks mostly declined overnight.

via Yahoo Finance|
#asco#business#ivonescimab
J&J’s Erleada combo before surgery shows strong early cancer clearance and longer time to progression
health1 month ago

J&J’s Erleada combo before surgery shows strong early cancer clearance and longer time to progression

A late-stage trial in high‑risk localized or locally advanced prostate cancer found that adding Johnson & Johnson’s Erleada (apalutamide) to hormone therapy before and after prostate removal increased the chance of having little to no detectable cancer at surgery (8.9% vs 1%), cut the risk of cancer spread or death by about 20% (and 29% with a full year of therapy), and extended the average time before needing subsequent treatment to over six years, suggesting a potential paradigm shift pending expanded approvals.

via Reuters|
#apalutamide#asco#erleada
Triple-action cancer jab wipes out head-and-neck tumours in international trial
health1 month ago

Triple-action cancer jab wipes out head-and-neck tumours in international trial

An international trial of 102 patients with HPV-negative head and neck cancer found that amivantamab, a subcutaneously injected jab, shrank tumours in 43 patients and completely eradicated them in 15, including in cancers resistant to chemotherapy and immunotherapy. The triple-action antibody blocks EGFR and MET and stimulates the immune system, and showed manageable side effects with most patients able to continue treatment; median overall survival was 12.5 months. The drug is also being explored in other cancers and results were to be presented at ASCO.

via The Guardian|
#amivantamab#asco#egfr
Kras-targeting pill doubles survival in metastatic pancreatic cancer, experts say
health1 month ago

Kras-targeting pill doubles survival in metastatic pancreatic cancer, experts say

A daily pill called daraxonrasib doubled median survival in a 500-patient trial of metastatic pancreatic cancer, from about 6.5–6.7 months with chemotherapy to 13.2 months, and it had fewer side effects. The drug inhibits Kras, a common cancer driver, and experts call the results landscape-changing and potentially game-changing, though access to the drug remains a key challenge.

via The Guardian|
#asco#daraxonrasib#health
GLP-1 Diabetes Drugs Hint at Slowing Cancer Spread, Early Observational Findings
health1 month ago

GLP-1 Diabetes Drugs Hint at Slowing Cancer Spread, Early Observational Findings

New findings from the Cleveland Clinic, presented at the ASCO meeting, suggest GLP-1 medications may be linked to reduced metastatic progression in several obesity-related cancers (notably non-small cell lung, breast, colorectal, and liver cancers) when compared with DPP-4 inhibitors. The study is observational and not peer‑reviewed, and it does not prove GLP-1s kill cancer cells or should be used for cancer prevention. Researchers caution that more rigorous, randomized trials are needed before changing cancer treatment guidelines.

via HuffPost|
#asco#cancer-progression#glp-1
GLP-1 diabetes drugs linked to slower cancer progression in early study
health1 month ago

GLP-1 diabetes drugs linked to slower cancer progression in early study

An observational analysis of over 10,000 cancer patients who started GLP-1 drugs after diagnosis found slower progression in four of seven cancers, with the strongest effects in lung and breast cancer, compared with a matched group on DPP-4 inhibitors. The study is not peer‑reviewed and cannot prove causation; randomized trials are needed to confirm any anti‑cancer effects. Researchers discuss possible mechanisms, including tumor GLP-1 receptor interactions, interference with glycolysis, and immune modulation, and conclude GLP-1 drugs appear safe for patients with cancer using them for diabetes or obesity, though they are not a cancer therapy.

via NBC News|
#asco#cancer-progression#diabetes-drugs